Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Keeping Track: Opana ER Abuse Deterrence Claim Withdrawn; Third Neulasta Biosimilar Submitted; Keytruda Cleared In Head And Neck Cancer

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

Advertisement

Related Content

Opana Safety Review Will Set Tone For Opioid Regulation Under Trump
Endo’s Opana ER, Generic Oxymorphone Safety Get US FDA Panel Review
Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation
Heron's Sustol Faces Competition With Narrower Label Than Expected
Deal Worth Up to $464m Advances MEI Drug, Diversifies Helsinn's Portfolio
Opdivo's Failure In First-Line Lung Cancer Prompts Rethink On Trial Endpoints
Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol
Keeping Track: More Bumps On The Abuse-Deterrent Opioid Road
Keeping Track: Alkermes' Aristada Approval; Bristol's Daklinza Submission; Lilly's Breakthrough
Keeping Track: FDA Clears Big Batch Of Products; 'Breakthrough' For Bristol HIV Drug

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118955

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel